Session 104 - 12th CROI

Home

Session 104 Poster Abstracts
Adherence, Quality of Life, and Factors Related to Treatment
Friday, 1:30 - 3:30 pm
Hall A

614	Cognitive-behavioral Intervention to Enhance Adherence to ART: A Randomized Clinical Trial (CCTG 578) Glenn Wagner*¹, D Kanouse¹, L Miller², E Daar², M Witt², C Diamond³, J Tilles³, C Kemper⁴, R Larsen⁵, E Seefried⁶, A McCutchan⁶, R Haubrich⁶, and California Collaborative Treatment Group (CCTG) ¹Rand Corp, Santa Monica, CA, USA; ²Harbor-UCLA Med Ctr, Univ of California, Los Angeles, Torrance, USA; ³Univ of California, Irvine, USA; ⁴Santa Clara Valley Med Ctr, San Jose, CA, USA; ⁵Univ of Southern California, Los Angeles, USA; and ⁶Univ of California, San Diego, USA
615	Factors Associated with ART Adherence and Medication Errors in Injection Drug Users Julia Arnsten*¹, M Gourevitch², K Handley³, K Knight⁴, A Knowlton⁵, L Metsch⁶, D Vlahov⁷, and the INSPIRE Team ¹Albert Einstein Coll of Med, Bronx, NY, USA; ²New York Univ Sch of Med, NY, USA; ³Hlth Resources and Svcs Admin, Washington, DC, USA; ⁴Univ of California, San Francisco, Ctr for AIDS Prevention Studies, USA; ⁵Johns Hopkins Univ, Baltimore, MD, USA; ⁶Univ of Miami, FL, USA; and ⁷New York Academy of Med, NY, USA
616	95% Adherence Is Not Necessary for Viral Suppression to Less than 400 Copies/mL in the Majority of Individuals on NNRTI Regimens David Bangsberg*, S Weiser, D Guzman, and E Riley San Francisco Gen Hosp, Univ of California, USA
617	Health-related Quality of Life with Tipranavir in Combination with an Optimized Background Regimen in 2 Randomized Clinical Trials Albert Wu*¹, I C Huang¹, F Lobo², and R Berzon³ ¹Johns Hopkins Univ, Baltimore, MD, USA; ²Boehringer Ingelheim Pharma Inc, Ridgefield, CT, USA; and ³Boehringer Ingelheim GmbH, Ingelheim, Germany
618	Participation in Randomized Clinical Trials at the Royal Free Hospital: Characteristics of Those Included and Effect on Treatment Outcomes Colette Smith*¹, C Sabin¹, M Johnson², M Youle², F Lampe¹, Z Cuthbertson², A Carroll², and A Phillips¹ ¹Royal Free and Univ Coll Med Sch, London, UK and ²Royal Free Hosp, London, UK
619	Racial Differences in Efavirenz Discontinuation in Clinical Practice Richard Moore*, J Keruly, K Gebo, and G Lucas Johns Hopkins Univ, Baltimore, MD, USA